March 31, 2022 | Cogstate, Decentralized trials, Impetus Digital, Natalie Yeadon, Pam Ventola, brain health, central rating, central scoring, clinical insights, clinical trials, cognitive testing, digital assessments, rare disease
Dr. Pam Ventola, Senior Science Director at Cogstate, shares how the company is working to optimize brain health assessments in rare disease and pediatric clinical trials, and how this can help advance the development of new medicines and enable earlier clinical insights. She also discusses cognitive testing as part of decentralized trials, the role of central rating and central scoring, the development of indication-specific COAs for rare disease trials, and much more.
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Even before the concept of physical/social distancing was born, Impetus Digital was a strong advocate for virtual collaboration. In our latest video, we explore another key benefit of asynchronous online…
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person.
At Impetus Digital, the health and wellbeing of our staff, clients, advisors, and their families is always our top priority. Recently, we have seen high numbers of advisors cancel their…
Impetus Digital shares its Top 10 list of the most important advisor questions.
Our online solutions are not just for advisory boards – find out how one client leveraged the Impetus InSite Platform® for a virtual journal club.
